Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SIRAGUSA, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.881
EU - Europa 12.710
AS - Asia 10.569
SA - Sud America 1.963
Continente sconosciuto - Info sul continente non disponibili 1.153
AF - Africa 307
OC - Oceania 29
Totale 53.612
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.245
SG - Singapore 3.904
IT - Italia 3.045
RU - Federazione Russa 2.919
CN - Cina 2.464
BR - Brasile 1.495
DE - Germania 1.383
FI - Finlandia 1.067
HK - Hong Kong 1.025
VN - Vietnam 952
UA - Ucraina 933
PL - Polonia 709
GB - Regno Unito 644
FR - Francia 576
JP - Giappone 444
BD - Bangladesh 413
IE - Irlanda 390
CA - Canada 361
SE - Svezia 308
IN - India 268
KR - Corea 230
NL - Olanda 177
TR - Turchia 149
AR - Argentina 138
IQ - Iraq 104
MX - Messico 104
ES - Italia 88
AT - Austria 86
RO - Romania 82
BE - Belgio 75
CO - Colombia 75
ID - Indonesia 74
EC - Ecuador 73
VE - Venezuela 73
CI - Costa d'Avorio 72
PK - Pakistan 72
ZA - Sudafrica 67
UZ - Uzbekistan 57
CR - Costa Rica 50
IR - Iran 45
MY - Malesia 43
SA - Arabia Saudita 41
CL - Cile 39
MA - Marocco 39
CH - Svizzera 38
JM - Giamaica 35
GR - Grecia 31
PH - Filippine 29
PY - Paraguay 28
AE - Emirati Arabi Uniti 27
EG - Egitto 26
JO - Giordania 26
KE - Kenya 24
TW - Taiwan 24
EE - Estonia 23
UY - Uruguay 23
IL - Israele 22
DZ - Algeria 21
LT - Lituania 21
ET - Etiopia 20
AU - Australia 19
NP - Nepal 19
HN - Honduras 17
KZ - Kazakistan 17
AL - Albania 16
QA - Qatar 16
LB - Libano 15
CZ - Repubblica Ceca 14
OM - Oman 13
TN - Tunisia 13
BG - Bulgaria 12
DO - Repubblica Dominicana 12
AZ - Azerbaigian 11
GT - Guatemala 11
MD - Moldavia 10
PE - Perù 10
SV - El Salvador 10
TH - Thailandia 10
DK - Danimarca 9
NI - Nicaragua 9
PT - Portogallo 9
RS - Serbia 9
TT - Trinidad e Tobago 9
BH - Bahrain 8
BO - Bolivia 8
EU - Europa 8
HR - Croazia 7
MM - Myanmar 7
NZ - Nuova Zelanda 7
AO - Angola 6
BY - Bielorussia 6
HU - Ungheria 6
KG - Kirghizistan 6
PR - Porto Rico 6
PS - Palestinian Territory 6
SY - Repubblica araba siriana 6
KH - Cambogia 5
KW - Kuwait 5
LY - Libia 4
PA - Panama 4
Totale 52.411
Salva come PNG Salva come JPEG
Città #
Ashburn 3.195
Singapore 2.506
Fairfield 2.385
San Jose 2.171
Chandler 1.249
Houston 1.247
Woodbridge 1.247
Wilmington 1.003
Hong Kong 981
Seattle 943
Cambridge 756
Council Bluffs 688
Ann Arbor 633
Zgierz 599
Palermo 503
Moscow 489
Jacksonville 468
Beijing 451
Tokyo 416
Santa Clara 392
Los Angeles 389
Medford 389
Dublin 382
New York 334
Dallas 321
Helsinki 321
Frankfurt am Main 315
Ho Chi Minh City 306
Des Moines 294
Lauterbourg 260
Boardman 257
Princeton 257
Altamura 251
Hanoi 240
Nanjing 237
Milan 188
Lawrence 187
Hefei 186
Chicago 181
San Diego 177
Buffalo 150
Dearborn 146
Rome 144
The Dalles 141
São Paulo 135
Tulsa 122
Orem 100
Phoenix 95
London 93
Ludwigshafen am Rhein 88
Atlanta 81
Columbus 80
Shenyang 80
Brooklyn 76
Toronto 76
Nuremberg 72
Abidjan 71
Brussels 71
Denver 71
Tianjin 69
Nanchang 66
Stockholm 65
Warsaw 65
Amsterdam 63
Hebei 60
Montreal 57
Washington 57
Seongnam 56
Changsha 53
Zhengzhou 49
Naperville 48
Jinan 46
Chennai 45
Guangzhou 45
Lappeenranta 43
Rio de Janeiro 43
Izmir 42
Jiaxing 42
San José 41
Shanghai 41
Tashkent 41
San Francisco 40
San Paolo di Civitate 40
Philadelphia 39
Baghdad 38
Brasília 38
Bremen 38
Mumbai 38
Munich 38
Poplar 38
Springfield 37
Vienna 36
Turin 35
Da Nang 34
Falls Church 34
Redwood City 34
Verona 34
Ottawa 33
Boston 32
Cardiff 32
Totale 31.511
Salva come PNG Salva come JPEG
Nome #
Cardiovascular events and intensity of treatment in polycythemia vera. 678
Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica 673
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 509
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep 436
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 416
Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses 403
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 357
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 343
Kinesiotaping for the Treatment of Haematomas in Haemophiliacs: a Case Control Study 342
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 337
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity 326
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 314
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 294
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 291
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 287
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 287
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report 275
Health-related quality of life and psychological well-being in elderly patients with haemophilia 274
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature 272
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 270
Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study 270
Successful Treatment of Gastrointestinal Bleeding With Recombinant Factor VIIa After Kidney Transplantation in Patients With Pancytopenia. 267
Acquired haemophilia in cancer: A systematic and critical literature review 267
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia 264
EGFR genomic alterations in cancer: prognostic and predictive values 258
Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study 254
Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management 252
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry 252
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 246
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 245
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 245
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study 243
Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma 242
Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry 241
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature 241
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS) 240
Erythrocyte deformability and hemorheological profile in multiple myeloma 240
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study 239
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 239
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series 236
null 231
Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy 230
Integrated Multi-Omic Profiling of Immune, Soluble, and Microbial Signatures Identifies Predictors of Multiple Myeloma Evolution 229
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 228
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 228
Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis 227
Deferral of assessment of pulmonary embolism 226
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis 226
The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. 225
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. 225
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy 225
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 225
Immunosenescence and lymphomagenesis 221
Multiple Myeloma-Derived Extracellular Vesicles Induce Osteoclastogenesis through the Activation of the XBP1/IRE1α Axis 221
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin 220
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. 218
Rivaroxaban for thromboprophylaxis in acutely ill medical patients 218
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 217
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 216
Cardio-oncology in multiple myeloma: is it time for a specific focus? 216
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation 215
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 215
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 214
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 214
Clinical implications of discordant early molecular responses in CML patients treated with imatinib 213
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up 212
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 211
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 211
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 210
Mapping Cell-Cell Communication Dynamics Across the Spectrum of Multiple Myeloma Evolution Using Single-Cell Transcriptomics 208
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease 208
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY 206
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 206
Aspirin for preventing the recurrence of venous thromboembolism 205
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 204
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 204
PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE 203
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, of both? 202
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. 202
ENDOGENOUS THROMBIN POTENTIAL IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOSIS 201
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues 201
Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study 200
Long term outcomes of patients with cerebral vein thrombosis: a multicenter study. 200
Gastrointestinal bleeding in patients with von Willebrand disease; how long we can wait for surgery? 199
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. 199
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results 199
D-dimer testing: advantages and limitation in emergency medicine for managing acute venous thromboembolism 198
Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients 198
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 198
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 197
La profilassi chirurgica di pazienti con carenza congenita di FVII 196
Clostridium difficile Induced Inflammasome Activation and Coagulation Derangements 195
Absence of Residual Vein Thrombosis after an Episode of Idiopathic Deep Vein Thrombosis: Short-Term Anticoagulation Is Safe. The "Extended Dacus Study". 195
Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins 195
Cardiovascular risk factor in MPN patients 194
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association 191
Adverse Events in Treatment of Inherited Factor VII Deficiency: Final Analysis of the STER 190
Le emergenze emorragiche in ematologia 189
Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey 189
Trombosi portale mesenterica idiopatica in paziente con doppia mutazione eterozigote del gene C677T e del gene A1298C della MTHFR 188
Totale 24.912
Salva come PNG Salva come JPEG
Categoria #
all - tutte 178.062
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.143 0 0 0 130 84 160 148 155 350 396 204 516
2022/20233.912 392 733 96 405 411 619 225 307 449 45 157 73
2023/20242.042 91 286 167 280 153 356 215 88 26 58 39 283
2024/20254.822 164 268 242 459 195 164 378 365 401 518 572 1.096
2025/202620.053 1.126 794 1.020 1.592 2.081 2.789 2.562 1.985 1.690 2.591 896 927
2026/20275.004 976 1.133 2.521 374 0 0 0 0 0 0 0 0
Totale 53.612